Home
 /
Papers
 /
Neuroscience
 /
Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology
Preprint
Open access
Top 1% · Validated by QED

Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology

Richard Drexler, Belgin Yalçın, Rebecca Mancusi +15 more
December 2025
 ·
bioRxiv
 ·
DOI 
10.64898/2025.12.10.693579
99
%
QED Score
QED Impressions

This paper overturns the assumption that only glutamatergic neurons drive glioma, establishing that serotonergic raphe circuits fuel tumor proliferation via 5HT2A—and that psilocybin, increasingly used in cancer patients, accelerates malignant growth.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

Serotonergic neurons from the dorsal and median raphe nuclei promote high-grade glioma proliferation through circuit-specific projections that activate the 5HT2A receptor on glioma cells, while gliomas reciprocally induce serotonergic neuronal hyperactivity and progressive serotonin release in the tumor microenvironment, establishing a pathogenic feed-forward loop that can be therapeutically disrupted by 5HT2A antagonism.

See full analysis
Main Claim 1 –

Serotonergic neurons drive circuit-specific glioma proliferation

Supporting evidence

  • Circuit-specific serotonergic glioma growth conserved across tumor models
  • Chronic serotonergic stimulation cumulatively accelerates glioma growth, reduces survival
  • Serotonergic activity releases NCAM-1 and ICAM-1 to promote growth
Main Claim 2 –

Serotonergic activity triggers glioma calcium transients

Supporting evidence

  • Chronic serotonergic stimulation induces persistent glioma calcium signaling
Main Claim 3 –

Glioma growth promotion requires 5HT2A receptor activation

Supporting evidence

  • Serotonin dose-dependently activates glioma receptors to drive proliferation
  • HTR2A is the predominant serotonin receptor in human gliomas
Main Claim 4 –

5HT2A antagonism suppresses glioma growth and extends survival

Supporting evidence

  • Mirtazapine reduces glioma proliferation via 5HT2A antagonism

Abstract

High-grade gliomas are lethal brain cancers that are powerfully regulated by glutamatergic neurons through activity-dependent paracrine factors and functional neuron-to-glioma synapses. Here, we report that serotonergic neurons promote the proliferation of high-grade gliomas throughout the brain. Serotonergic neuronal activity drives circuit-specific increases in high-grade glioma proliferation, calcium transients, and reduced survival. This growth-promoting effect is chiefly mediated by activation of the serotonin (5-hydroxytryptamine; 5HT) receptor 5HT2A on glioma cells. Knock out or pharmacological blockade of 5HT2A receptors in glioma abrogated the glioma growth-promoting effects of serotonergic neuronal activity, while serotonergic psychedelic drugs robustly promote malignant cell proliferation. Gliomas alter serotonergic neuronal activity patterns, resulting in elevated serotonin release into the tumor microenvironment. Together, these findings uncover pathogenic, feed-forward interactions between serotonergic neurons and glioma cells.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?